We invest in entrepreneurial companies that are developing pre-clinical or early clinical pharmaceutical assets.

We currently manage approximately $500 million in capital. Our typical investment size is from $5 to $20 million. Our investment experience spans all therapeutic areas and we have made investments in both private and public opportunities in both the United States and Europe.

We bring to bear many strengths in evaluating potential investment opportunities and assisting management in addressing scientific, strategic and operational issues. Our partners have unmatched drug development experience and have been responsible for the development, approval and commercialization of drugs having in excess of $50 billion in peak sales. We take a very active role in our portfolio companies and we work energetically with management to develop and grow their businesses.